RXST

RxSight, Inc.

$4.90

0.82%
SectorHealthcareIndustryMedical DevicesCountryUnited States

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017.

Source: Yahoo Finance
AI summary

Price & performance

1M+6.6%
3M-20.2%
YTD-51.9%
1Y-44.6%
52-week range—
Beta1.37
Full chart and returns against a benchmark

Q-Score

43/ 100

Quality against peers; 50 is the peer median.

Growth42
Risk47
Performance30
Valuation69
Profitability48
Leverage34
Sentiment56
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$134.5M-3.9%
Net income-$38.9M
Net margin-29.0%-9.3 pts
Historical fundamentals

Revenue exposure

0%of revenue from outside the US
United States100%
Largest customer10%
Regions, segments, customers and suppliers

Valuation

RXSTIndustryP/E—29.61P/S1.783.49EV/EBITDA—18.38P/B0.813.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 3next report
EPS estimate$-0.19
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate